rdoe_persona_userprofile
rdoe_persona_select_up

Launch & commercialization

With the largest installed base of over 10,000 BenchMark IHC/ISH staining platforms worldwide, and a powerful affiliate network in 100+ countries, our partners have the broadest access to patients.

Biomarker awareness

By activating early adopters, we gather early real-world performance data to generate evidence that drives awareness and supports uptake. We also engage with payers and facilitate medical and sales training for our affiliates.

Day one readiness

We bridge the gap to ensure there is no delay in patient access to your therapy. We engage earlier with KOLs and centers of excellence, prepare labs and deliver pathologist education to establish testing readiness.

 

Launch excellence & rapid adoption

Marketing and market access teams coordinate launches globally and locally, ensuring all critical tools for planning and execution of global launch strategy are available across Roche and pharma affiliates, worldwide.

cancer strain

CASE STUDY

Bridging the path to CDx success

Find out how we enabled significant access to personalized therapy for cancer patients.

Our commercial strength is unrivaled

Dominating market preference
Dominating market preference
 

Our traditional and accelerated commercialization models build awareness and drive adoption through a broad range of activities from pre-launch readiness to post-launch marketing.

Global launch coordination
Global launch coordination
 
Driven by a global plan, regional Roche affiliates collaborate with the local pharma partner to implement key commercialization activities.
Building pathologist confidence
Building pathologist confidence
 
Our emphasis on industry-leading pathologist education advances familiarity and knowledge leading to greater confidence in assay interpretation.